What are the challenges in scaling up the production of cell-based therapies involving B cells?

Sep 7, 2017 ... The US Food and Drug Administration granted regular approval to tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) for the treatment of patients up to ... Jun 13, 2024 ... Mechanisms regulating the induction and durability of B and T cell memory ... Mechanisms of immune cell killing/clearance of infected cells ... Jan 17, 2025 ... Cutaneous B-cell lymphoma is a cancer that starts in the white blood cells and attacks the skin. It often causes a lump or group of lumps on the skin. Jan 4, 2024 ... 10:07 Go to channel Understanding Diffuse Large B-Cell Lymphoma with Bruce Cheson, MD, FACP, FAAAS, FASCO Lymphoma Research Foundation B-cell acute lymphoblastic leukemia, or B-ALL, is a bone marrow and blood cancer. B-ALL occurs at any age but more commonly in children. Không có mô tả Feb 21, 2025 ... A framework, Mal-ID (machine learning for immunological diagnosis), to interpret the variable sequences of B and T cell receptors (BCRs and TCRs) from human ... B cells are at the centre of the adaptive humoral immune system and are responsible for mediating the production of antigen-specific immunoglobulin (Ig) ... Aug 19, 2024 ... This trial represents the largest randomized study of radiotherapy in PMBCL to date. Despite encountering challenges due to unexpectedly good ... When a naïve or memory B cell is activated by an antigen, it proliferates and differentiates into an antibody-secreting effector cell, known as a plasmablast or ...